Search

Your search keyword '"Dominguez, Javier"' showing total 153 results
Start Over Author "Dominguez, Javier" Language english
153 results on '"Dominguez, Javier"'

7. Whole genome analysis of Gram-negative bacteria using the EPISEQ CS application and other bioinformatic platforms

Author

Garza-Ramos, Ulises, Rodríguez-Medina, Nadia, Córdova-Fletes, Carlos, Rubio-Mendoza, Daira, Alonso-Hernández, Christopher J., López-Jácome, Luis Esaú, Morfín-Otero, Rao, Rodríguez-Noriega, Eduardo, Rojas-Larios, Fabián, Vázquez-Larios, María del Rosario, Ponce-de-Leon, Alfredo, Choy-Chang, Elena Victoria, Franco-Cendejas, Rafael, Martinez-Guerra, Bernardo Alfonso, Morales-de-La-Peña, Cecilia Teresita, Mena-Ramírez, Juan Pablo, López-Gutiérrez, Eduardo, García-Romo, Ricardo, Ballesteros-Silva, Bertha, Valadez-Quiroz, Alejandro, Avilés-Benítez, Laura Karina, Feliciano-Guzmán, José Manuel, Pérez-Vicelis, Talia, Velázquez-Acosta, María del Consuelo, Padilla-Ibarra, Cecilia, López-Moreno, Laura Isabel, Corte-Rojas, Reyna Edith, Couoh-May, Carlos Antonio, Quevedo-Ramos, María Angelina, López-García, Maribel, Chio-Ortiz, Gabriela, Gil-Veloz, Mariana, Molina-Chavarria, Alejandro, Mora-Domínguez, Javier Paul, Romero-Romero, Daniel, May-Tec, Francisco Javier, and Garza-González, Elvira

Published
2023
Full Text
View/download PDF

16. Clinical course and prognostic factors of COVID-19 infection in an elderly hospitalized population

Author

de Miguel, Rosa, Romero, Miriam, Lago, Mar, García-Quero, Cristina, Plaza, Cristina, Sainz-Costa, Talía, Rivas-Vila, Susana, Sánchez, Blanca, Torres, Celia García, Martínez-Tobar, Lucía, Hernandez-Pérez, María, Racionero, Pablo, Mir-Ihara, Patricia, Peña-López, Jesús, Bautista-Barea, Marta, Benítez, Alexa P., Rodríguez-Merlos, Pablo, Barcenilla, María, Basilio, María San, Valencia, María, Romero-Martín, Ricardo, Boto de los Bueis, Ana, de la Hoz-Polo, Adriana, del Pino-Cidad, María, Coca-Robinot, Javier, González-Ferrer, Bárbara, Fernández-Pérez, Pedro, Mogollón, Isabel, Montoro-Romero, María S., Villalaín, Isabel, del Hierro-Zarzuelo, Almudena, Hernández-Martín, Irene, Domínguez, Javier, Luna, Alberto, Montoro, Soledad, Sánchez-Orgaz, Margarita, Amorena, Gloria, Lavín-Dapena, Cosme, Negreiros, Aaron Zapata, Mostaza, Jose M., García-Iglesias, Francisca, González-Alegre, Teresa, Blanco, Francisco, Varas, Marta, Hernández-Blanco, Clara, Hontañón, Victor, Jaras-Hernández, María J., Martínez-Prieto, Mónica, Menéndez-Saldaña, Araceli, Cachán, María L., Estirado, Eva, and Lahoz, Carlos

Published
2020
Full Text
View/download PDF

20. Diagnostic Performance of Point-of-Care High-Sensitivity Troponin in the Exclusion of Non-ST-Elevation Myocardial Infarction in the Emergency Department.

Author

Zalama-Sánchez, Daniel, del Pozo Vegas, Carlos, Sanz-García, Ancor, de Santos-Castro, Pedro Ángel, Presencio-Dominguez, Javier, González-Izquierdo, Pablo, Sánchez-Ramón, Susana, Pinilla-Arribas, Leyre Teresa, Baladrón-Segura, Manuel, Cheayeb-Morán, Jaldún, Fernandez-García, María, Velasco de Cos, Guillermo, López-Izquierdo, Raúl, and Martín-Rodríguez, Francisco

Subjects
NON-ST elevated myocardial infarction, CHEST pain, HOSPITAL emergency services, POINT-of-care testing, RECEIVER operating characteristic curves, TROPONIN
Abstract

Background: This study evaluates the diagnostic performance of high-sensitivity troponin using point-of-care testing (POCT) devices compared with main laboratory measurements for ruling out non-ST-elevation myocardial infarction (NSTEMI) in emergency department (ED) patients presenting with non-traumatic chest pain. Methods: This multicenter, observational, prospective, non-interventional study was conducted in two Spanish hospitals from 1 June to 31 December 2023 and included adult patients presenting with non-traumatic chest pain admitted to the ED. High-sensitivity troponin levels were measured using both the Siemens Atellica® VTLi POCT device and main laboratory testing, with data collected on analytical results and measurement times. Results: Of the 201 patients who met the inclusion criteria, a significant correlation was observed between the POCT and laboratory assays. The area under the curve (AUC) of the ROC curve was consistently greater than 0.9, indicating a high diagnostic accuracy for ruling out NSTEMI. In addition, measurement times were significantly reduced using POCT compared to the core laboratory. Conclusion: These results suggest that high-sensitivity troponin POCT devices offer comparable diagnostic performance to traditional laboratory methods for the diagnosis of NSTEMI in the emergency department, potentially speeding up clinical decisions and optimizing resource utilization. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Clinical Evaluation of MyoCare in Europe (CEME): study protocol for a prospective, multicenter, randomized, double-blinded, and controlled clinical trial.

Author

Alvarez-Peregrina, Cristina, Sanchez-Tena, Miguel Angel, Martinez-Perez, Clara, Villa-Collar, Cesar, Montero-Torrejon, Alejandro, Lopez-Muñoz, Alfredo, Ruiz-Hernandez, Alicia, Gonzalez-Abad, Ana Isabel, Santos-de-Melo, Antonio Manuel, de Corcuera Terrero, Beatriz, Gargallo-Martinez, Beatriz, Mataix-Palao, Carolina, Boeck-Maier, Christina, Celdran-Vivancos, Diego Asensio, Rodriguez, Isabel, Vega-Dominguez, Javier, Martinho-Antunes, João Manuel, Garay-Dominguez, Jose Carlos, Recalde-Zurita, Jose Ignacio, and Reina-Gallego, Juan Luis

Abstract

Background: Myopia prevalence has been increasing in the last decades, and its pathological consequences, including myopic maculopathy and high myopia-associated optic neuropathy, are now one of the most common causes of visual impairment. It is estimated that by 2050, more than 50% of Europeans and Americans will be myopes, which is alarming due to the high morbidity of myopes over − 6.00D. Once myopia has appeared, there are different options with scientific evidence to try to slow the axial length growth. Ophthalmic lenses are the less invasive treatment to control myopia, and there is evidence about the efficacy of different designs, mainly in the Asiatic population. However, new designs have been launched, and it is not known if efficacy is the same between Asiatic and European subjects. Thus, we have set up a randomized, controlled, double-blind, and multicenter trial to investigate the efficacy of a new design of ophthalmic lenses for myopia control in European children. Methods: A 2-year prospective, multicenter, randomized controlled, and double-blind clinical trial is used to investigate the efficacy of a new design of ophthalmic lenses to slow the progression of myopia. Three hundred children aged from 6 to 13 years old will be recruited and randomly assigned to a study or control group. The study group will be composed of 150 children wearing MyoCare while the control group will be composed of 150 children wearing Clearview. The inclusion criteria will be myopia with a spherical equivalent between − 0.75D and − 5.00D, astigmatism < 1.50D, and anisometropia < 1.00D and having a historical evolution of at least − 0.50 The primary outcome is to compare the mean annual progression of the spherical equivalent between both groups. The secondary outcomes are axial length, choroidal thickness, phorias, and accommodative status of both groups. Discussion: This study will be the first randomized and controlled clinical trial in European children with spectacle lenses based on simultaneous competing defocus. The results will shed light on the clinical evidence of spectacle lenses relying on this new design for the management of myopia with results of efficacy in the non-Asiatic population. Trial registration: EU Clinical Trials Register (EudraCT) 2022–001696. Registered on 27 April 2022. ClinicalTrials.gov NCT05919654. Registered on 26 June 2023. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results